Seres Therapeutics, Inc. MCRB
$2.15
+2.88%
at last close
Market Cap$21.31 million
P/E Ratio—
Div Yield—
Volume19.2K
52-Week Range
$1.68$29.98
Analyst Ratings
- Consensus
- Buy — 2 Buy · 0 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $17.00 (+690.7% upside)
Key Stats
- Today's Range
- $2.12 – $2.26
- 50-Day Range
- $1.68 – $5.95
- 52-Week Range
- $1.68 – $29.98
- Volume
- 19K shs
- Average Volume
- 79K shs
- Market Cap
- $21.31 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 47.82%
- Days to Cover
- 28.86
About Seres Therapeutics, Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Related Stocks
Compare head-to-head: MCRB vs LLY·MCRB vs JNJ·MCRB vs ABBV·MCRB vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.